Recent Updates
Recently added Catalysts

Deep TMS

Phase 2

Machado Joseph Disease (SCA3) | Unknown | Other |BrainsWay Ltd.|Last Updated: Jan 25, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02039206The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph DiseasePHASE2 COMPLETED 20Feb 1, 2014Jun 1, 2016Jan 25, 20181 Israel
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Scale for the Assessment and Rating of Ataxia (SARA)
30 days
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TreatmentEXPERIMENTALDeep TMS
Interventions
NameTypeDescription
Deep TMSDEVICE1Hz Stimulation
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * SCA3 patients aged 20 - 80 years, with detectable clinical signs and confirmed genetic diagnosis. Exclusion Criteria: 1. Patients who have concomitant epilepsy. 2. History of seizure or heat convulsion. 3. Patients on neuroleptics. 4. Patients with dementia (MMSE\<25) or any...

Countries:Israel
Unlock Eligibility Criteria